FDA Alerts on Risks From Merck’s Keytruda in Multiple Myeloma Following Halted Trials

Aug 31, 2017, 11:38 by Michael Croft

RAPS | Today, FDA released an alert and summary findings from two halted Merck clinical trials evaluating the use of Keytruda (pembrolizumab) combined with other treatments in patients with multiple myeloma.

August 31, 2017 | Today, FDA released an alert and summary findings from two halted Merck clinical trials evaluating the use of Keytruda (pembrolizumab) combined with other treatments in patients with multiple myeloma. RAPS